AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15954914 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO administration (50 units per kg once per week) in group II
Number of subjects: 36
Study 15954914 — intervention group
Group type: COMPARATOR
Intervention: No EPO treatment in group III
Number of subjects: 36
Study 15954914 — intervention group
Group type: COMPARATOR
Intervention: CKD stage 1 to 2 (group I)
Number of subjects: 36
Study 15954914 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (controls)
Number of subjects: 36
Study 11931316 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbation conditions (randomly altered amplitudes)
Number of subjects: 0
Study 11931316 — intervention group
Group type: EXPERIMENTAL
Intervention: No-perturbation conditions (equal-amplitude tones)
Number of subjects: 0
Study 11931316 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall analysis of across-frequency correlation functions
Number of subjects: 0
Study 11931316 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual data analysis
Number of subjects: 0
Study 9755272 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine/Midazolam (K/M)
Number of subjects: 260
Study 9755272 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl/Midazolam (F/M)
Number of subjects: 260
Study 9755272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 260
Study 8046602 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular release formulation of tiaprofenic acid (300 mg)
Number of subjects: 4
Study 8046602 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release (SR) formulation of tiaprofenic acid (300 mg)
Number of subjects: 4
Study 3186477 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS) by pacifier for 5 minutes
Number of subjects: 24
Study 3186477 — intervention group
Group type: COMPARATOR
Intervention: No pacifier (Control)
Number of subjects: 24
Study 5309493 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 14000
Study 5309493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14000
Study 11602855 — intervention group
Group type: EXPERIMENTAL
Intervention: Celsior solution
Number of subjects: 100
Study 11602855 — intervention group
Group type: COMPARATOR
Intervention: University of Wisconsin (U.W.) solution
Number of subjects: 100
Study 31342893 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based intervention program encouraging healthy eating habits and physical activity.
Number of subjects: 97
Study 31342893 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 97
Study 31342893 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined school and home-based intervention for overweight or obese adolescents.
Number of subjects: 97
Study 29982083 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy (HSE) induction
Number of subjects: 34
Study 29982083 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 34
Study 27235377 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized counseling on using the surrounding built environment to increase MVPA
Number of subjects: 60
Study 27235377 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care lifestyle modification counseling (Control)
Number of subjects: 60
Study 24394747 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine Transdermal Delivery System (BTDS)
Number of subjects: 0
Study 24394747 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22017520 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg/day
Number of subjects: 253
Study 22017520 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 253
Study 20537751 — intervention group
Group type: EXPERIMENTAL
Intervention: Euglycaemia during moderate aerobic exercise
Number of subjects: 7
Study 20537751 — intervention group
Group type: COMPARATOR
Intervention: Hyperglycaemia during moderate aerobic exercise
Number of subjects: 7
Study 17652730 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 73
Study 17652730 — intervention group
Group type: COMPARATOR
Intervention: Other antiepileptic drugs
Number of subjects: 73
Study 17652730 — intervention group
Group type: COMPARATOR
Intervention: Normally developing children
Number of subjects: 73
Study 16325366 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane supplementation (400 mg/m²) after epirubicin infusion
Number of subjects: 20
Study 16325366 — intervention group
Group type: COMPARATOR
Intervention: Epirubicin-based chemotherapy without dexrazoxane
Number of subjects: 20
Study 11990278 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 microg kg(‐1) over 30 s, followed by an infusion of 0.1 microg kg min(‐1) (group R)
Number of subjects: 40
Study 11990278 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 microg kg(‐1) over 30 s, followed by an infusion of saline (group A)
Number of subjects: 40
Study 10710173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0.325 mg/kg)
Number of subjects: 8
Study 10710173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0.650 mg/kg)
Number of subjects: 8
Study 10710173 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10710173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine (0.325 mg/kg) and (0.650 mg/kg)
Number of subjects: 8
Study 7815715 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal indomethacin 50 mg plus epidural 0.1 mg buprenorphine in 8 ml of 0.25% bupivacaine and 15 micrograms buprenorphine in 1 ml of 0.25% bupivacaine at 1 ml.h‐1 for 48 h
Number of subjects: 40
Study 7815715 — intervention group
Group type: COMPARATOR
Intervention: Epidural 0.1 mg buprenorphine in 8 ml of 0.25% bupivacaine and 15 micrograms buprenorphine in 1 ml of 0.25% bupivacaine at 1 ml.h‐1 for 48 h
Number of subjects: 40
Study 2765342 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-tuning, closed-loop controller regulating isoflurane concentration
Number of subjects: 33
Study 2765342 — intervention group
Group type: COMPARATOR
Intervention: Manual control of arterial pressure
Number of subjects: 33
Study 938189 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate hydrochloride
Number of subjects: 61
Study 938189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 30558978 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline neurocognitive assessment (Brief Assessment of Cognition for Schizophrenia)
Number of subjects: 294
Study 27544133 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic-Assisted Combined Hysterectomy (LACH)
Number of subjects: 101
Study 27544133 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic-Assisted Vaginal Hysterectomy (LAVH)
Number of subjects: 101
Study 26013003 — intervention group
Group type: EXPERIMENTAL
Intervention: PT + active PDT
Number of subjects: 0
Study 26013003 — intervention group
Group type: COMPARATOR
Intervention: PT + placebo PDT
Number of subjects: 0
Study 23671058 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 40
Study 23671058 — intervention group
Group type: COMPARATOR
Intervention: Social skills training (Control)
Number of subjects: 40
Study 23671058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (MI and Control)
Number of subjects: 40
Study 22164930 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided group medical art therapy (MAT) for 6 weeks, facilitated by a MAT therapist.
Number of subjects: 20
Study 22164930 — intervention group
Group type: COMPARATOR
Intervention: Routine clinical visit only (Control group B).
Number of subjects: 20
Study 19809344 — intervention group
Group type: EXPERIMENTAL
Intervention: EP-2104R (4 mumol/kg intravenous bolus injection)
Number of subjects: 52
Study 16969009 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 0.5 mg ACTH-depot doses for the entire duration of pregnancy
Number of subjects: 424
Study 16969009 — intervention group
Group type: EXPERIMENTAL
Intervention: Series of three 0.5 mg ACTH-depot injections every other day in the first and/or second trimester
Number of subjects: 424
Study 16969009 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 424
Study 14748820 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg
Number of subjects: 9
Study 14748820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 11264604 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water immersion during labor
Number of subjects: 1237
Study 9250558 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromfenac 50 mg (3 times/day for 3 days)
Number of subjects: 12
Study 9250558 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times/day for 3 days)
Number of subjects: 12
Study 8220804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg once daily for two weeks
Number of subjects: 107
Study 8220804 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 107
Study 8220804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 3470961 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 treatment group (0.2 ng/kg body weight/min and 15,000 I.U. heparin/d for 10 days)
Number of subjects: 0
Study 3470961 — intervention group
Group type: COMPARATOR
Intervention: Control group (3 x 500 mg aspirin and 15,000 I.U. heparin/d)
Number of subjects: 0
Study 3470961 — intervention group
Group type: EXPERIMENTAL
Intervention: PGE1 treatment group
Number of subjects: 0
Study 3470961 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 30273586 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of extended‐release liposomal bupivacaine (Exparel)
Number of subjects: 100
Study 30273586 — intervention group
Group type: COMPARATOR
Intervention: 20 mL of placebo (saline)
Number of subjects: 100
Study 27925141 — intervention group
Group type: COMPARATOR
Intervention: Traditional renal protective food (control)
Number of subjects: 81
Study 27925141 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional food one (FF1)
Number of subjects: 81
Study 27925141 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional food two (FF2)
Number of subjects: 81
Study 24986773 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity (BMI > 30 kg/m²)
Number of subjects: 1924
Study 22967782 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone induction
Number of subjects: 64
Study 22967782 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone maintenance dose
Number of subjects: 64
Study 20920764 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 92
Study 20920764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 18455480 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep-tissue massage
Number of subjects: 0
Study 18455480 — intervention group
Group type: EXPERIMENTAL
Intervention: Superficial touch
Number of subjects: 0
Study 18455480 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 15907239 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Misoprostol (50 microg, 4 hourly to a maximum of four doses)
Number of subjects: 214
Study 15907239 — intervention group
Group type: COMPARATOR
Intervention: PGE2 vaginal pessary (at 6 hourly intervals up to two doses)
Number of subjects: 214
Study 12769340 — intervention group
Group type: EXPERIMENTAL
Intervention: iCNOP (mitoxantrone 20 mg/m2, i.v., d.1)
Number of subjects: 143
Study 12769340 — intervention group
Group type: COMPARATOR
Intervention: CHOP (standard regimen)
Number of subjects: 143
Study 12769340 — intervention group
Group type: EXPERIMENTAL
Intervention: iCNOP
Number of subjects: 143
Study 12769340 — intervention group
Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 143
Study 10501238 — intervention group
Group type: EXPERIMENTAL
Intervention: CAIV-T
Number of subjects: 19
Study 10501238 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7485077 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide 4 mg po q6h
Number of subjects: 36
Study 7485077 — intervention group
Group type: COMPARATOR
Intervention: Octreotide 150 micrograms CI
Number of subjects: 36
Study 7485077 — intervention group
Group type: COMPARATOR
Intervention: Octreotide at higher dosage levels (dose escalated to maximum of 2,400 micrograms)
Number of subjects: 36
Study 1683697 — intervention group
Group type: EXPERIMENTAL
Intervention: Apraclonidine
Number of subjects: 17
Study 1683697 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7345096 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselled group
Number of subjects: 53
Study 7345096 — intervention group
Group type: COMPARATOR
Intervention: Uncounselled group (Control)
Number of subjects: 53
Study 30575093 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual community (closed Facebook community for peer-to-peer interaction)
Number of subjects: 121
Study 30575093 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher adherence to the virtual community
Number of subjects: 121
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 500 mg
Number of subjects: 40
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 1000 mg
Number of subjects: 40
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 2000 mg
Number of subjects: 40
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 4000 mg
Number of subjects: 40
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 250 mg (MAD)
Number of subjects: 40
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 500 mg (MAD)
Number of subjects: 40
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin 1000 mg (MAD)
Number of subjects: 40
Study 28347318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 28347318 — intervention group
Group type: EXPERIMENTAL
Intervention: Surotomycin (SAD and MAD)
Number of subjects: 40
Study 27295864 — intervention group
Group type: COMPARATOR
Intervention: 0.12% CHX mouthrinse
Number of subjects: 60
Study 27295864 — intervention group
Group type: COMPARATOR
Intervention: 0.2% CHX mouthrinse
Number of subjects: 60
Study 27295864 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ADS CHX mouthrinse
Number of subjects: 60
Study 27295864 — intervention group
Group type: COMPARATOR
Intervention: 0.2% CHX
Number of subjects: 60
Study 24485063 — intervention group
Group type: EXPERIMENTAL
Intervention: Vulnerability-stress intervention
Number of subjects: 416
Study 24485063 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogenetic intervention
Number of subjects: 416
Study 24485063 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention
Number of subjects: 416
Study 24485063 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 416
Study 22621684 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Number of subjects: 0
Study 22621684 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab
Number of subjects: 0
Study 19432126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of active vitamin D3 and alendronate
Number of subjects: 2000
Study 19432126 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment of risedronate and vitamin K2
Number of subjects: 2000
Study 17222256 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based virtual microscopy
Number of subjects: 0
Study 17222256 — intervention group
Group type: COMPARATOR
Intervention: Conventional light microscopy
Number of subjects: 0
Study 15488108 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 0
Study 15488108 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy (CBT)
Number of subjects: 0
Study 15488108 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual therapy (CBT)
Number of subjects: 0
Study 11159242 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine and fentanyl 2 microg/mL
Number of subjects: 106
Study 11159242 — intervention group
Group type: EXPERIMENTAL
Intervention: Levobupivacaine and fentanyl 3 microg/mL
Number of subjects: 106
Study 11159242 — intervention group
Group type: COMPARATOR
Intervention: Levobupivacaine control
Number of subjects: 106
Study 9779700 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone, high‐dose cytarabine, and cisplatin (DHAP)
Number of subjects: 188
Study 9779700 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to relapse
Number of subjects: 188
Study 7930247 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-stay coronary observation unit
Number of subjects: 1516
Study 7930247 — intervention group
Group type: COMPARATOR
Intervention: Comparison patients (admitted to wards, stepdown/intermediate care units, or coronary care unit)
Number of subjects: 1516
Study 7930247 — intervention group
Group type: COMPARATOR
Intervention: Comparison patients (discharged home from the emergency department)
Number of subjects: 1516
Study 3207529 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine formulation
Number of subjects: 0
Study 3207529 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher concentrations of amethocaine (12%) in formulation C
Number of subjects: 0
Study 3207529 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulations A and B (hydrophilic)
Number of subjects: 0
Study 3207529 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C (oil-in-water cream)
Number of subjects: 0
Study 2119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg/day during 1 week)
Number of subjects: 18
Study 2119530 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2119530 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline infusions (0.1 and 0.4 nmol kg‐1 min‐1)
Number of subjects: 18
Study 2119530 — intervention group
Group type: EXPERIMENTAL
Intervention: CWT (colour word conflict test)
Number of subjects: 18
Study 786348 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline 5 mug/ml added to 1% etidocaine hydrochloride
Number of subjects: 0
Study 786348 — intervention group
Group type: COMPARATOR
Intervention: 1% etidocaine hydrochloride plain
Number of subjects: 0
Study 786348 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine hydrochloride
Number of subjects: 0
Study 786348 — intervention group
Group type: COMPARATOR
Intervention: Plain etidocaine
Number of subjects: 0
Study 786348 — intervention group
Group type: EXPERIMENTAL
Intervention: Etidocaine with adrenaline
Number of subjects: 0
Study 786348 — intervention group
Group type: COMPARATOR
Intervention: Plain lignocaine
Number of subjects: 0
Study 31956998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified regimen with rifampin 15 mg/kg and levofloxacin for the first 60 days
Number of subjects: 237
Study 31956998 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 15 mg/kg
Number of subjects: 237
Study 31956998 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid exposure
Number of subjects: 237
Study 31754048 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80-160 mg daily for 7 days)
Number of subjects: 60
Study 31754048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28385346 — intervention group
Group type: EXPERIMENTAL
Intervention: Early administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Number of subjects: 5580
Study 28385346 — intervention group
Group type: COMPARATOR
Intervention: Late administration of SAP (1.5 g of cefuroxime, intravenous infusion over 2-5 min)
Number of subjects: 5580
Study 26175059 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss through dietary modification and physical activity
Number of subjects: 81
Study 22966789 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride
Number of subjects: 0
Study 22966789 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0
Study 22966789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21162469 — intervention group
Group type: EXPERIMENTAL
Intervention: INROADS educational intervention
Number of subjects: 0
Study 21162469 — intervention group
Group type: COMPARATOR
Intervention: Control group of demographically similar nurses
Number of subjects: 0
Study 19057207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar transurethral resection of the prostate
Number of subjects: 0
Study 19057207 — intervention group
Group type: COMPARATOR
Intervention: Monopolar transurethral resection of the prostate
Number of subjects: 0
Study 17286624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (initiated at 300 mg/day, titrated to a maximum of 900 mg b.i.d.)
Number of subjects: 0
Study 17286624 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Number of subjects: 0
Study 15190802 — intervention group
Group type: EXPERIMENTAL
Intervention: Parapost
Number of subjects: 90
Study 15190802 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct post
Number of subjects: 90
Study 15190802 — intervention group
Group type: EXPERIMENTAL
Intervention: Parapost cement
Number of subjects: 90
Study 15190802 — intervention group
Group type: COMPARATOR
Intervention: ZPC cement
Number of subjects: 90
Study 15190802 — intervention group
Group type: COMPARATOR
Intervention: HY-Bond cement
Number of subjects: 90
Study 11309009 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine 7.5 mg. ml‐1
Number of subjects: 30
Study 11309009 — intervention group
Group type: EXPERIMENTAL
Intervention: ropivacaine 7.5 mg. ml‐1 + 1 microg. ml‐1 fentanyl
Number of subjects: 30
Study 9136493 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.1 mg/kg
Number of subjects: 34
Study 9136493 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.3 mg/kg
Number of subjects: 34
Study 9136493 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 0.5 mg/kg
Number of subjects: 34
Study 9136493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9113119 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron (Navoban)
Number of subjects: 115
Study 9113119 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone plus Metoclopramide
Number of subjects: 115